Titre:
  • Continuous versus intermittent tamoxifen versus intermittent/alternated tamoxifen and medroxyprogesterone acetate as first line endocrine treatment in advanced breast cancer: an EORTC phase III study (10863).
Auteur:Beex, Louk; Rose, Carsten; Mouridsen, Henning; Jassem, J.; Nooij, Marianne; Estape, J.; Paridaens, R.; Piccart-Gebhart, Martine; Gorlia, Thierry; Lardenoije, S.; Baila, L.
Informations sur la publication:European journal of cancer, 42, 18, page (3178-3185)
Statut de publication:Publié, 2006-12
Sujet CREF:Sciences bio-médicales et agricoles
Mots-clés:Advanced breast cancer
Alternated endocrine therapy
Intermittent endocrine therapy
Medroxyprogesterone acetate
Randomised study
Tamoxifen
MeSH keywords:Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
Breast Neoplasms -- drug therapy
Disease-Free Survival
Drug Resistance, Neoplasm
Female
Humans
Medroxyprogesterone Acetate -- administration & dosage
Medroxyprogesterone Acetate -- adverse effects
Middle Aged
Tamoxifen -- administration & dosage
Tamoxifen -- adverse effects
Note générale:Clinical Trial, Phase III
Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Langue:Anglais
Identificateurs:urn:issn:0959-8049
info:doi/10.1016/j.ejca.2006.08.020
info:pii/S0959-8049(06)00765-9
info:scp/33845224929
info:pmid/17045796